Cytosine nucleoside compound based on glycine, preparation method and application thereof, and bactericidal and antiviral composition
By developing glycine-based cytosine nucleoside compound Y05, the problem of difficult creation of target pesticides in the prior art on plant virus diseases is solved, and efficient bactericidal and antiviral effects are achieved, which is suitable for the prevention and control of various plant diseases.
Patent Information
- Application Number
- CN202411268053.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to effectively create target pesticides against plant virus diseases, and lacks efficient bactericidal and antiviral pesticides.
Develop glycine-based cytosine nucleoside compounds, inhibit viral RNA synthesis by simulating the binding of cytidine triphosphate to RNA-dependent RNA polymerase, and prepare compound Y05 with significant antiviral activity and bactericidal Use in combination of agents or antiviral agents.
Compound Y05 significantly inhibits the growth and viral replication of a variety of plant pathogens, provides efficient bactericidal and antiviral effects, is suitable for the prevention and treatment of a variety of plant diseases, and improves the protection efficiency of crops.
Smart Images

Figure CN119080854A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a glycine-based cytosine nucleoside compound, a preparation method and application thereof, and a bactericidal and antiviral composition. Background Art
[0002] The creation of targeted pesticides has become an important direction in pesticide scientific research. It not only effectively controls pests and diseases, but also improves crop yield and quality, ensures food safety and promotes agricultural development. In recent years, research in this field has made rapid progress at home and abroad. For example, the new domestic fungicide Flubeneteram targets the pathogen succinate dehydrogenase, the herbicide Monosulfuron targets the weed acetolactate synthase, and the insecticide Cycloxaprid targets the nicotinic acetylcholine receptor (nAChR) of pests; in addition, the insecticide Spiropyridon developed by Syngenta targets insect acetyl-CoA carboxylase. However, the creation of targeted pesticides for plant viral diseases remains a challenge. Summary of the invention
[0003] The object of the present invention is to provide a glycine-based cytosine nucleoside compound, a preparation method and application thereof, and a bactericidal and antiviral composition, which have excellent bactericidal, antiviral and insecticidal activities.
[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0005] The present invention provides a glycine-based cytosine nucleoside compound having a structure shown in Formula 1:
[0006]
[0007] In formula 1, n=0~6.
[0008] The present invention provides a method for preparing the glycine-based cytosine nucleoside compound, comprising the following steps:
[0009] Mixing a glycine compound, cytosine nucleoside, a condensing agent and a first organic solvent to carry out a condensation reaction to obtain a condensation product;
[0010] The condensation product, trifluoroacetic acid and a second organic solvent are mixed, and after deprotection, extraction, washing, separation, concentration and purification are sequentially performed to obtain a glycine-based cytosine nucleoside compound having a structure shown in Formula 1;
[0011] The glycine compound has a structure shown in Formula 2:
[0012]
[0013] The cytosine nucleoside has a structure shown in Formula 3:
[0014]
[0015] The condensation product has a structure shown in Formula 4:
[0016]
[0017] Preferably, the mass ratio of the glycine compound to cytosine nucleoside is 5-15:4-6.
[0018] Preferably, the condensing agent includes O-benzotriazole-tetramethyluronium hexafluorophosphate or 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; the mass ratio of the condensing agent to cytidine nucleoside is 1:1-2;
[0019] The first organic solvent includes N,N-diisopropylethylamine or triethanolamine; the usage ratio of the condensing agent to the first organic solvent is 2-6 g:5-10 mL.
[0020] Preferably, the condensation reaction temperature is 4 to 25° C. and the time is 2 to 12 hours.
[0021] Preferably, the usage ratio of the condensation product to trifluoroacetic acid is 2-6 g:1-4 mL.
[0022] Preferably, the temperature of the deprotection is 18 to 25° C., and the time is 1 to 3 hours.
[0023] Preferably, the purification is performed using a C18 chromatographic column, and the reagents used for the purification include acetonitrile and water, and the volume ratio of acetonitrile to water is 1-3:4-7.
[0024] The present invention provides the use of the glycine-based cytosine nucleoside compound described in the above technical scheme or the glycine-based cytosine nucleoside compound prepared by the preparation method described in the above technical scheme in the preparation of insecticides, fungicides or anti-plant virus agents.
[0025] The present invention provides a fungicide and antiviral composition for plant diseases, which comprises, by weight percentage, 1-99% of the glycine-based cytosine nucleoside compound described in the above technical solution and 1-99% of a drug; the drug is a fungicide or an antiviral agent.
[0026] The cytosine nucleoside compound provided by the present invention introduces glycine into the cytosine nucleoside lead structure, thereby providing a new high-efficiency candidate compound for the creation of new pesticides.
[0027] The antibacterial activity and antiviral activity results of the present invention show that the cytosine nucleoside compound Y05, as a nucleoside analog, is an important target for the design and synthesis of antiviral compounds because the RNA-dependent RNA polymerase (RdRp) of plant viruses is a key enzyme in the viral replication process. Compound Y05 binds to the active site of the RdRp enzyme by simulating the cytidine triphosphate (CTP) substrate of viral RNA, thereby inhibiting the synthesis of viral RNA and exhibiting significant antiviral activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is the molecular docking diagram of compound Y05 and viral RdRp protein;
[0029] Figure 2 This is a microthermal kinetic analysis diagram of compound Y05 and viral RdRp;
[0030] Figure 3 This is the microcalorimetric analysis diagram of compound Y05 and viral RdRp mutant. DETAILED DESCRIPTION
[0031] In the present invention, unless otherwise specified, the required raw materials or reagents are commercially available products well known to those skilled in the art.
[0032] The present invention provides a glycine-based cytosine nucleoside compound having a structure shown in Formula 1:
[0033]
[0034] In formula 1, n=0~6.
[0035] In the present invention, n is preferably 0, 1 or 2.
[0036] The glycine-based cytosine nucleoside compounds provided by the present invention are specifically
[0037]
[0038] The present invention provides a method for preparing the glycine-based cytosine nucleoside compound, comprising the following steps:
[0039] Mixing a glycine compound, cytosine nucleoside, a condensing agent and a first organic solvent to carry out a condensation reaction to obtain a condensation product;
[0040] The condensation product, trifluoroacetic acid and a second organic solvent are mixed, and after deprotection, extraction, washing, separation, concentration and purification are sequentially performed to obtain a glycine-based cytosine nucleoside compound having a structure shown in Formula 1;
[0041] The glycine compound has a structure shown in Formula 2:
[0042]
[0043] The cytosine nucleoside has a structure shown in Formula 3:
[0044]
[0045] The condensation product has a structure shown in Formula 4:
[0046]
[0047] The present invention mixes a glycine compound, cytosine nucleoside, a condensing agent and a first organic solvent, and performs a condensation reaction to obtain a condensation product.
[0048] In the present invention, the glycine compounds and cytosine nucleoside are both commercially available products (Shanghai BiDe Pharmaceutical Technology Co., Ltd.).
[0049] In the present invention, the mass ratio of the glycine compound to cytosine nucleoside is preferably 5-15:4-6, more preferably 5-12:4-5, and further preferably 8-10:4-5.
[0050] In the present invention, the condensing agent preferably includes O-benzotriazole-tetramethyluronium hexafluorophosphate (HBTU) or 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), and the mass ratio of the condensing agent to cytidine nucleoside is preferably 1:1-2, more preferably 1:1; the first organic solvent preferably includes N,N-diisopropylethylamine (DIEA) or triethanolamine (TEA); the dosage ratio of the condensing agent to the first organic solvent is 2-6g:5-10mL, more preferably 5-6g:6-9mL.
[0051] In the present invention, preferably, the glycine compound and cytosine nucleoside are added to a reaction bottle, vacuumed, a first organic solvent is added, and then a condensation agent is added, and the obtained mixture is subjected to a condensation reaction.
[0052] In the present invention, the temperature of the condensation reaction is preferably 4 to 25° C., more preferably 25° C., and the time is 2 to 12 h, more preferably 6 to 10 h.
[0053] The present invention preferably uses silica gel thin layer chromatography to monitor the progress of the condensation reaction, and uses a mixed solution with a volume ratio of ethyl acetate:petroleum ether=1-4:2-5 as the chromatography liquid, and more preferably 2-3:2-4.
[0054] After the condensation reaction is completed, the present invention preferably purifies the obtained reaction product to obtain a condensation product; the purification is preferably carried out using a C18 chromatographic column, and the reagents used for the purification preferably include acetonitrile and water, and the volume ratio of acetonitrile to water is preferably 2 to 5:1 to 3, more preferably 2:1, 5:3 or 5:2. The present invention has no special restrictions on the specifications or models of the C18 chromatographic column, and any C18 chromatographic column known in the art can be used.
[0055] After obtaining the condensation product, the present invention mixes the condensation product, trifluoroacetic acid and a second organic solvent, removes the protecting group, and then sequentially extracts, washes, separates, concentrates and purifies to obtain a glycine-based cytosine nucleoside compound with a structure shown in Formula 1.
[0056] In the present invention, the usage ratio of the condensation product to trifluoroacetic acid is preferably 2-6 g:1-4 mL, more preferably 3-5 g:2-4 mL.
[0057] In the present invention, the second organic solvent is preferably dichloromethane; the volume ratio of the second organic solvent to trifluoroacetic acid is preferably 1.5 to 8:1, more preferably 2 to 6:1.
[0058] In the present invention, the temperature for deprotection is preferably 18 to 25° C., more preferably 20 to 25° C., and the time is preferably 1 to 3 hours, more preferably 2 to 3 hours.
[0059] In the present invention, the condensation product is preferably added to a flask, vacuumed, a second organic solvent and trifluoroacetic acid are added, and the resulting mixture is subjected to deprotection under stirring conditions.
[0060] The present invention preferably uses silica gel thin layer chromatography to monitor the progress of the deprotection reaction, and uses a mixed solution with a volume ratio of ethyl acetate: petroleum ether = 1-4:2-5 as the chromatography liquid, and more preferably 2-3:3-4.
[0061] The present invention preferably uses a saturated sodium bicarbonate aqueous solution to quench the deprotection reaction, then extracts with ethyl acetate, separates the ethyl acetate layer, washes the obtained ethyl acetate phase with water and a saturated sodium chloride aqueous solution in sequence, purifies the obtained product, separates and concentrates under vacuum, and obtains a glycine-based cytosine nucleoside compound with a structure shown in Formula 1.
[0062] In the present invention, the purification is preferably carried out using a C18 chromatographic column, and the model of the C18 chromatographic column is preferably Agilent TC-C18; the reagents used for the purification preferably include acetonitrile and water, and the volume ratio of acetonitrile to water is preferably 1-3:4-7, and more preferably 2-3:5.
[0063] The present invention has no particular limitation on the separation and concentration, and the separation and concentration may be carried out according to processes well known in the art.
[0064] In the present invention, the preparation reaction formula of the glycine-based cytosine nucleoside compound is:
[0065]
[0066] The present invention provides the use of the glycine-based cytosine nucleoside compound described in the above technical scheme or the glycine-based cytosine nucleoside compound prepared by the preparation method described in the above technical scheme in the preparation of insecticides, fungicides or anti-plant virus agents.
[0067] Cytidine nucleoside analogs are biologically active substances that, when used as fungicides in pesticides, usually work by interfering with the nucleic acid synthesis of pathogens. These analogs can mimic the structure of natural nucleosides, thereby binding to the nucleic acid polymerase of pathogens and hindering the normal synthesis of DNA or RNA. Since the reproduction and survival of pathogens depend on the replication and transcription of their genetic material, the intervention of cytidine nucleoside analogs will cause the pathogens to be unable to carry out normal cell division and the transmission of genetic information, ultimately leading to the death of the pathogens. This mechanism has a highly effective inhibitory effect on plant pathogens and helps protect crops from diseases.
[0068] When cytosine nucleoside analogs are used as insecticides in pesticides, their mechanism of action is mainly through interfering with the growth and development of insects. These compounds can simulate the nucleoside structure in insects and interact with the enzyme system in insects, especially affecting the DNA or RNA synthesis of insects. Since the growth, development and reproduction of insects depend on the normal replication and transcription of their genetic material, the intervention of cytosine nucleoside analogs will cause the cell division of insects to be blocked, affecting their normal physiological functions. This interference may cause abnormal development or even death of insect larvae, thereby effectively controlling the number of pests and protecting crops from damage. It has the characteristics of strong targeting and environmental friendliness.
[0069] The present invention provides a fungicide and antiviral composition for plant diseases, which comprises, by weight percentage, 1-99% of the glycine-based cytosine nucleoside compound described in the above technical solution and 1-99% of a drug; the drug is a fungicide or an antiviral agent.
[0070] When the agent is a fungicide, the glycine-based cytosine nucleoside compound is combined with any one or two of the commercial fungicides to form a fungicide composition for preventing and controlling agricultural, forestry and horticultural plant diseases.
[0071] In the present invention, the commercial fungicide preferably includes: tebuconazole, thiocyclazole, difenoconazole, propiconazole, thiosilazole, myclobutanil, cyproconazole, thiosilazole, flutriafol, hexaconazole, metconazole, tetrathioimidazole, triadimenol, trimethoprim, bifenthrin, diniconazole, penconazole, nitrobenzazole, methiconazole, oxadiazole, imidoconazole, silthioazole, triadimefon, fenpropimorph, fenpropimorph, spiroxafil, tridemorph, dodecamorph, thiomorph, chlorfenapyr, pyrimidine oxime, pyrimidine sulfonate, thiamethoxam, thiocyclanil, myclobutanil, allylisothiazole, prochloraz, tricyclazole, oxamectin, furazolidone, imazalil, thioconazole, activated ester , thiophanate-methyl, oxamitazole, rice blast, thiophanate-methyl, mancozeb, maneb, propineb, maneb, methanamide, zinc thiram, thiram, sulfur, copper preparations, lime sulfur, copper preparations, sulfur, 8-hydroxyquinoline copper, triphenyltin, lime sulfur, chlorothalonil, captan, folpet, azoxystrobin, trifloxystrobin, kresoxim-methyl, pyraclostrobin, picoxystrobin, benoxystrobin, thiopyraclostrobin, kresoxim-methyl, kresoxim-methyl, UBF-307, KZ-165, carbendazim, methyl thiophanate-methyl, thiophanate-methyl, benomyl, mai sui ning, metalaxyl, bensulfur, metalaxyl, fenamidone, isoprodinil, procymidone, vinyl sclerotin, ethyl bromide, gram Bacteriocarb, foltan, sclerotin, cyproconazole, carboxin, cyanamide, thiocarb, thiamethoxam, oxycarboxin, thiamethoxam, silthiocarb, thiamethoxam, penthiopyrad, iprovalicarb, cyfluorophenamid, fluopicolide, mandipropamid, ethaboxam, dichlorocyanamide, sulfamethoxam, thiomethoxam, chlorothiamethoxam, cyclamic acid, furazolidone, oxazolidone, furamide, cyprodinil, pyrimidine, pyrimidine, thiomethoxam, thiomethoxam, thiopyrad, pentachloronitrobenzene, pentachloronitrobenzene Long, dithianon, biguanide acetate, dithiocarb, benzylsulfuronamide, biguanide salt, doguoding, phthalocyanine, propamocarb, isoprofenamide, ethoprofen, sulfaquinoline, pyroquinol, quinoline, ethyl phosphine, isothiocyanate, dichlorvos, methyl tolclofos, pyraclofos, paclobutrazol, streptomycin, kasugamycin, chlorothalonil, blasticidin, polyoxin, validamycin, cypermethrin, fludioxonil, bromocriptine, thiocyanate, thiophanate-methyl, cymoxanil, oxathiapiprolin, cyclamoxadone, cyclamoxadone, imidacloprid, dichlorocyanamide, cyazofamid, dinitrocrotonate, sulfaquinoline, rice blast, benzyl phosphine, tetrachlorophthalide, boscalid, hypersensitive protein, thiophanate-methyl, pyraclostrobin, and seed coating.
[0072] In the present invention, the dosage form of the fungicide composition preferably includes seed treatment emulsion, aqueous emulsion, microemulsion, suspoemulsion, capsule suspension, water-soluble granules, fine granules, soluble concentrate, poison valley, block poison bait, granular poison bait, sheet poison bait, concentrated poison bait, slow-release block, electrostatic spray, water-in-oil emulsion, smoke can, smoke candle, smoke tube, smoke stick, smoke sheet, smoke pill, gasifier, ointment, hot fog, cold fog, aerosol, solid-liquid mixed agent, liquid / liquid mixed agent, solid / solid mixed agent, lacquer, microgranule, tracking powder, oil suspension, oil dispersible powder, concentrated glue, pouring agent, seed coating agent, smear, film-forming oil agent, ultra-low volume liquid or steam release agent.
[0073] In the present invention, the plant diseases controlled by the fungicide composition preferably include rice seedling rot, tomato root rot, potato late blight, tobacco black shank, millet powdery mildew, grape downy mildew, yellow camp downy mildew, cucumber downy mildew, cucumber anthracnose, tomato gray mold, strawberry powdery mildew, corn gall smut, wheat rust, tobacco target spot, tobacco brown spot, potato late blight, and wheat fusarium rust.
[0074] In the present invention, the plants controlled by the fungicide composition preferably include rice, wheat, barley, oats, corn, sorghum, sweet potato, cassava, soybean, snow pea, broad bean, pea, mung bean, adzuki bean, cotton, sericulture, peanut, rapeseed, sesame, sunflower, beet, sugarcane, coffee, cocoa, ginseng, fritillaria, rubber, coconut, oil palm, sisal, tobacco, tomato, pepper, dream, cucumber, cabbage, celery, mustard tuber, beet, rapeseed, onion, garlic, watermelon, melon, cantaloupe, papaya, apple, citrus and peach, tea, wild vegetables, bamboo shoots, hops, pepper, banana, papaya, orchid, and poor view.
[0075] When the agent is an antiviral agent, the glycine-based cytosine nucleoside compound is combined with any one or two of the commercial antiviral agents to form an antiviral composition for preventing and controlling viral diseases of agricultural, forestry and horticultural plants.
[0076] In the present invention, the commercial antiviral agents preferably include: benzothiadiazole, thiazolamide, isothiazolamide, 4-methyl-1,2,3-thiadiazole-5-carboxylic acid, 4-methyl-1,2,3-thiadiazole-5-sodium carboxylate, 4-methyl-1,2,3-thiadiazole-5-carboxylic acid ethyl ester, 3,4-dichloroisothiazole-5-carboxylic acid, 3,4-dichloroisothiazole-5-sodium carboxylate, 3,4-dichloroisothiazole-5-carboxylic acid ethyl ester, DL-β-aminobutyric acid, virazole, anthofen, ningnanmycin, thioamide, thiazolamide or salicylic acid, pyrimidine, dichloroisonicotinic acid, allyl isothiocyanate, hydroxylamine, viroxim, and thiothioate.
[0077] In the present invention, the dosage forms processed by the antiviral composition preferably include: seed treatment emulsion, aqueous emulsion, microemulsion, suspoemulsion, capsule suspension, water-soluble granules, fine granules, soluble concentrate, poison valley, block poison bait, granular poison bait, sheet poison bait, concentrated poison bait, slow-release block, electrostatic spray, water-in-oil emulsion, smoke can, smoke candle, smoke tube, smoke stick, smoke sheet, smoke pill, gasifier, ointment, hot fog, cold fog, aerosol, solid-liquid mixed agent, liquid / liquid mixed agent, solid / solid mixed agent, lacquer, microgranule, tracking powder, oil suspension, oil dispersible powder, concentrated glue, pouring agent, seed coating agent, smear, film-forming oil agent, ultra-low volume liquid agent, steam release agent.
[0078] In the present invention, the plant diseases controlled by the antiviral composition preferably include: tobacco mosaic virus, cucumber mosaic virus, rice dwarf disease, yellow dwarf disease, stripe leaf blight, pepper mosaic virus, tobacco vein necrosis virus, corn dwarf mosaic virus, cauliflower mosaic virus, citrus virus disease, Jianlan orchid leaf virus, and Jianlan ringspot virus.
[0079] In the present invention, the plants controlled by the antiviral composition preferably include: rice, wheat, barley, oats, corn, sorghum, sweet potato, cassava, soybean, snow pea, broad bean, pea, mung bean, adzuki bean, cotton, sericulture, peanut, rapeseed, sesame, sunflower, beet, sugarcane, coffee, cocoa, ginseng, fritillaria, rubber, coconut, oil palm, sisal, tobacco, tomato, pepper, dream, cucumber, cabbage, celery, mustard tuber, beet, rapeseed, onion, garlic, watermelon, melon, cantaloupe, papaya, apple, citrus and peach, tea, wild vegetables, bamboo shoots, hops, pepper, banana, papaya, orchid, and poor view.
[0080] As another embodiment of the present invention, the agent is an insecticide, and the glycine-based cytosine nucleoside compound of the present invention is combined with any one or two of commercial insecticides to form an insecticidal composition for preventing and controlling agricultural, forestry and horticultural plant diseases.
[0081] In the present invention, the insecticide composition comprises, by mass percentage, 1 to 99% of the glycine-based cytosine nucleoside compound described in the above technical solution and 1 to 99% of the insecticide.
[0082] In the present invention, the commercial insecticides preferably include: cypermethrin, malathion, dichlorvos, deltamethrin, imidacloprid, cyfluthrin, profenofos, fipronil, permethrin, thiamethoxam, acetamiprid, fluazinam, methylphosphine, buprofezin, chlorflucythrin, pymetrozine, thiacloprid, clothianidin, thiamethoxam, pyriproxyfen, thiamethoxam, imidacloprid, thiacloprid, thiacloprid, thiacloprid, thiacloprid, thiacloprid, thiacloprid, thiacloprid, and thiacloprid.
[0083] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0084] Example 1
[0085] Preparation of compound Y03:
[0086] 5 g (tert-butyloxycarbonyl)glycine (purchased from Shanghai Bidex Pharmaceuticals Co., Ltd.) and 4 g cytidine were added to a 50 mL round-bottom flask, and the flask was evacuated. Then, 5 mL of dry N,N-diisopropylethylamine was added as a solvent, and 2 g of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate was added as a condensing agent. The resulting mixture was stirred at 25° C. for 8 h, and the reaction was monitored by silica gel thin layer chromatography. Ethyl acetate: petroleum ether = 1:2 (v / v) was used as the chromatographic liquid. The resulting reaction product was passed through a C18 chromatographic column (Agilent TC-C18) was purified with acetonitrile / water (v / v=2 / 1) to obtain tert-butyl (2-((1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-2-oxoethyl)carbamate (Y03-Compound III);
[0087] 2 g of Y03-compound III was added to a 50 mL round-bottom flask, and the mixture was evacuated. 6 mL of dichloromethane and 1 mL of trifluoroacetic acid were added. The resulting mixture was stirred at 25 °C for 1 h. The reaction was monitored by silica gel thin layer chromatography. Ethyl acetate:petroleum ether=2:3 (v / v) was used as the chromatographic liquid. The reaction was quenched with a saturated aqueous sodium bicarbonate solution. The mixture was extracted with ethyl acetate, and the ethyl acetate layer was separated. The ethyl acetate phase was washed with water and a saturated aqueous sodium chloride solution in sequence. The mixture was purified by a C18 column (Agilent TC-C18) with acetonitrile / water (v / v=1 / 5), separated and concentrated under vacuum to obtain 2-amino-N-(1-)3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide (compound Y03).
[0088] Example 2
[0089] Preparation of compound Y04:
[0090] 8 g (tert-butyloxycarbonyl) glycylglycine (purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.) and 5 g cytidine were added to a 50 mL round-bottom flask, and the mixture was evacuated. Then, 9 mL of dry triethanolamine was added as a solvent, and 5 g of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate was added as a condensation agent. The resulting mixture was stirred at 25° C. for 10 h, and the reaction was monitored by silica gel thin layer chromatography. Ethyl acetate: petroleum ether=3:2 was used as a chromatographic liquid. The resulting reaction product was purified by C18 column with acetonitrile / water (v / v=5 / 3) to obtain tert-butyl (2-((1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-2-oxoethyl)amino)-2,2-oxoethyl)carbamate (Y04-Compound III);
[0091] 3 g of Y04-compound III was added to a 50 mL round-bottom flask, and the mixture was evacuated. 7 mL of dichloromethane and 4 mL of trifluoroacetic acid were added, and the resulting mixture was stirred at 25 °C for 3 h. The reaction was monitored by silica gel thin layer chromatography. Ethyl acetate:petroleum ether=3:4 was used as the chromatographic liquid. The reaction was quenched with a saturated sodium bicarbonate solution, and extracted with ethyl acetate. The ethyl acetate layer was separated, and the ethyl acetate phase was washed with water and a saturated sodium chloride aqueous solution in sequence. The mixture was purified by a C18 chromatographic column (Agilent TC-C18) with acetonitrile / water (v / v=3 / 5), separated and concentrated under vacuum to obtain 2-amino-N-(2-)1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-2-oxoethyl)acetamide (compound Y04).
[0092] Example 3
[0093] Preparation of compound Y05:
[0094] 12 g (tert-butyloxycarbonyl) glycyl glycyl glycine (purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.) and 6 g cytidine were added to a 50 mL round-bottom flask, vacuumed, and then 9 mL of dry N,N-diisopropylethylamine was added as a solvent, and 6 g 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate was used as a condensing agent, and the mixture was stirred at 25°C for 6 hours. The reaction was monitored by silica gel thin layer chromatography, and ethyl acetate:petroleum ether=3:4 was used as a chromatographic liquid. The resulting reaction product was purified by C18 column with acetonitrile / water (v / v=5 / 2) to obtain tert-butyl (2-((2-(1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-2-oxoethyl)amino)carbamate (Y05-compound III);
[0095] 3 g of Y05-compound III was added to a 50 mL round-bottom flask, and the mixture was evacuated. 8 mL of dichloromethane and 1 mL of trifluoroacetic acid were added. The resulting mixture was stirred at 25 °C for 2 h. The reaction was monitored by silica gel thin layer chromatography. Ethyl acetate:petroleum ether=1:2 was used as the chromatographic liquid. The reaction was quenched with a saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The ethyl acetate layer was separated, and the ethyl acetate phase was washed with water and a saturated aqueous sodium chloride solution in sequence. The mixture was purified by a C18 column (Agilent TC-C18) with acetonitrile / water (v / v=3 / 5), separated and concentrated under vacuum to obtain 2-amino-N-(2-((1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)amino)-2-oxoethyl)amino)-2-oxoethyl)acetamide (compound Y05).
[0096] Table 1 Physicochemical parameters and structural parameters of cytosine nucleoside compounds prepared in Examples 1 to 3
[0097]
[0098]
[0099] Test Example 1
[0100] The mycelium growth rate method was used to determine the fungicidal or antibacterial activity of the compounds against a variety of plant pathogens. The test species were tobacco target spot pathogen (Rhizoctonia solani Kühn), rice sheath blight pathogen (Rhizoctonia solani), corn ear rot pathogen (Fusariumgminearum Schwabe), wheat fusarium rust pathogen (Gibberella zeae), pepper stem base rot pathogen (Rhizoctonia solani), and potato early blight pathogen (Alternaria solani.Sorauer), which can represent most of the species of pathogens occurring in the field in agricultural production.
[0101] The specific steps are:
[0102] The sample compounds were weighed and dissolved in sterile water, and the concentration was 5000 mg / L test reagents were prepared and placed in a low-temperature refrigerator for activity determination. Under sterile conditions, 0.33 mL or 0.66 mL of a 5000 mg / L agent (compound Y03, Y04 or Y05) was mixed with 33 mL of melted (60±5°C) PDA medium to prepare 33 mL of drug-containing medium with a concentration of 50 mg / L. 33 mL of drug-containing medium was evenly poured into 3 culture dishes with a diameter of 9 cm, 11 mL per dish. After the drug-containing medium in the dish condensed, the cultured pathogenic bacteria blocks with a diameter of 0.5 cm were inoculated and placed in a 28°C incubator for culture. After the colonies in the blank control were fully grown, the colony diameters of each treatment were measured by the cross method and the average was taken. The inhibition rate was calculated based on the average diameters of the blank control and the treated colonies after correction, and the inhibitory activity of each compound against various pathogens was determined by the mycelial growth rate method. After inoculation and cultivation, the colony diameter was measured and the inhibition rate was calculated according to the calculation formula. Each compound and control agent was repeated 3 times.
[0103] The bactericidal activity test results of the glycine-based cytosine nucleoside compounds of the present invention are as follows:
[0104] The results of mycelium growth rate determination are shown in Table 2.
[0105] Table 2 Antibacterial activity of cytosine nucleoside compounds of the present invention (inhibition rate % at 50 mg / L)
[0106] Pathogenic fungi Y03 Y04 Y05 Nicotiana tabacum 32.21 33.00 65.72 Rhizoctonia solani 27.40 19.28 81.88 Corn ear rot 72.54 49.86 48.33 Gibberella graminearum 61.06 49.17 33.81 Pepper stem rot 57.00 51.48 41.88 Alternaria solani 48.24 59.48 41.41
[0107] The results of Table 2 show that at 50 mg / L, the glycine-based cytosine nucleoside compounds of the present invention have different degrees of fungicidal activity against different pathogens. The inhibition rate of Y03 on six pathogens reached more than 27.40%, among which the best inhibition effect on corn ear rot and wheat scab was 72.54% and 61.06%, respectively. The inhibition rate of Y04 on six pathogens reached more than 19.28%, among which the best inhibition effect on pepper stem base rot and potato early blight was 51.48% and 59.48%, respectively. The inhibition rate of Y05 on six pathogens reached more than 33.81%, among which the best inhibition effect on tobacco target spot and rice sheath blight was 65.72% and 81.88%, respectively. Y03, Y04 and Y05 have different inhibitory effects on six pathogenic fungi. Among them, the inhibitory effect of Y03 on corn ear rot, wheat fusarium and pepper stem base rot is higher than that of Y04 and Y05. Y04 has the best inhibitory effect on potato early blight. The inhibitory effect of Y05 on tobacco target spot pathogen and rice sheath blight pathogen is higher than that of Y03 and Y04.
[0108] Test Example 2
[0109] Field efficacy test of compound Y05 in combination with fungicides.
[0110] The specific steps are: taking Yushu Township, Fushun City, Liaoning Province as the test site, conducting field efficacy tests on rice sheath blight.
[0111] The test drugs were 50 mg / L compound Y05, 24% thiofuran suspension, 20% validamycin soluble powder, 24% thiofuran-compound Y05 (mass ratio 1:1) suspension, and 20% validamycin-compound Y05 (mass ratio 1:1) soluble powder.
[0112] The field plot test set the application concentration to 100mL / 667m 2 , 2 times of application, the first time of application was at the end of June (rice breakout stage) and before closing. The second time of application was at rice breakout stage and heading stage.
[0113] The test survey was conducted in accordance with the criteria for field efficacy tests of pesticides (I) and the fungicide control of rice sheath blight (GB / T17980.20-2000). The degree of damage to rice leaves and leaf sheaths was graded, with plants as the unit. Each plot was sampled using the diagonal five-point sampling method. Ten clusters were surveyed at each point, and the most seriously ill clusters were selected from each cluster to record their disease levels. The disease index was counted before application, and the disease index was surveyed again 1-2 weeks after application. During the survey, the outermost 5 rows around each plot were skipped and not counted to eliminate the influence of duckweed and reduce the marginal effect.
[0114] The classification standards for rice sheath blight are as follows:
[0115] Disease level standards
[0116] Level 0: disease-free
[0117] Level 1: The fourth leaf and the leaf sheaths and leaves below it are infected (the flag leaf is the first leaf)
[0118] Level 3: The disease occurs on the third leaf and the leaf sheaths and leaves below it
[0119] The disease occurs on the second leaf and the leaf sheaths and leaves below level 5
[0120] Level 7 flag leaf blade and the leaf sheaths and leaves below it are infected
[0121] Level 9: The whole plant becomes ill and dies prematurely
[0122] The calculation formulas for disease index and control effect are as follows:
[0123]
[0124] Where: CK0——disease index of blank control area before application;
[0125] CK1——disease index of blank control area after application of pesticide;
[0126] PT0——disease index before application of pesticide in the treatment area;
[0127] PT1——Disease index after pesticide application in the pesticide treatment area.
[0128] The field control results of compound Y05 combined with fungicides are shown in Table 3:
[0129] Table 3 The efficacy of compound Y05 combined with fungicides against rice sheath blight
[0130]
[0131] Note: The application rates of the 6 treatment groups were the same.
[0132] The results in Table 3 show that the control effect of cytosine nucleoside compounds on rice sheath blight in the field at 50 mg / L is lower than that of the control agents 24% thiofuran suspension and 20% jinggangmycin soluble powder, which is 50.97% after the first application and 84.92% after the second application. After being used in combination with the two control agents, the relative control effect was greatly increased. Among them, after being used in combination with 24% thiofuran suspension, the control effect after the first application was increased to 59.78%, and the control effect after the second application was increased to 88.23%. After being used in combination with 20% jinggangmycin soluble powder, the control effect after the first application was increased to 70.07%, and the control effect after the second application was increased to 90.95%.
[0133] Test Example 3
[0134] The dead spot method was used to determine the antiviral activity of the compound against tobacco mosaic virus TMV. The specific steps are as follows:
[0135] First, accurately weigh 4 mg of the compound, dissolve it with 0.05 mL of distilled water, and then add 8 ml of distilled water containing 1% Tween 80 to prepare a test solution with a mass concentration of 500 mg / L. Prepare 500 mg / L of test solution of Ningnanmycin and oligosaccharide chain protein original drugs, and use this as the control agent, and spray the Tween 80 aqueous solution without the target compound as the blank control. Select 5-6 leaf heartleaf tobacco with consistent growth, spray the agent evenly on the surface of the test host leaves, and inoculate the virus 24 hours after spraying the agent (preventive effect). Spraying the agent 24 hours after inoculation with TMV is a therapeutic effect. In the test, take fresh virus-producing leaves, grind them into a homogenate with PBS buffer (pH = 7.2), spray corundum (240 mesh) on the leaves, and inoculate the 3rd and 4th leaves of each heartleaf tobacco plant by friction inoculation. Wash off the corundum on the leaf surface with clean water 15 minutes after inoculation. Observe and record the number of necrosis spots produced 48 hours after virus inoculation, and calculate the necrosis spot inhibition rate. The treatment agent and the control were repeated three times. The anti-TMV protective activity and therapeutic activity of the target compound were determined.
[0136] The antiviral activity test results of the glycine-based cytosine nucleoside compounds of the present invention are shown in Table 4.
[0137] Table 4 Anti-plant virus activity of cytosine nucleoside compounds (inhibition rate % at 500 mg / L)
[0138] Preventive activity Therapeutic activity Y03 33.77 49.71 Y04 48.57 44.01 Y05 69.25 62.73 Ningnanmycin 61.06 49.17 Oligosaccharide chain protein 57.00 51.48
[0139] Note: The dosage of the 5 treatment groups is the same.
[0140] The results in Table 4 show that the glycine-based cytosine nucleoside compounds synthesized by the present invention have good preventive and therapeutic activities against tobacco mosaic virus, with the preventive and therapeutic activities of Y03 being 33.77% and 49.71% respectively, and the preventive and therapeutic activities of Y04 being 48.57% and 44.01% respectively, both slightly lower than the control agents Ningnanmycin and oligosaccharide chain protein. The preventive and therapeutic activities of Y05 are the best, being 69.25% and 62.73% respectively, higher than the control agents.
[0141] Test Example 4
[0142] The antiviral effect of the product on potato virus Y was tested on tomatoes. The specific steps are as follows:
[0143] Compound Y03, Y04 or Y05 were prepared into test solution with a mass concentration of 80 mg / L, and Ningnanmycin and copper morpholine guanidine original drugs of the same concentration were used as controls, and spraying Tween 80 aqueous solution was used as a blank control. Four true leaf tomatoes in the field were selected, and the agent was evenly sprayed on the surface of the test host leaves. The virus PVY was inoculated 24 hours after the spraying of the agent (preventive activity), and the agent was sprayed 24 hours after the inoculation of PVY (therapeutic activity). Plant symptoms were observed and recorded 21 days after the virus was inoculated, and the inhibition rate was calculated by the disease index method. The treatment agent and the control were repeated three times.
[0144] The grading standard for tomato virus diseases is as follows: Level 0, no symptoms; Level 1, only slight mosaic or streaking on the upper leaves; Level 2, obvious mosaic or streaking on the upper leaves, leaf deformation, and mild dwarfing of the plant; Level 3, deformed leaves, many streaks and twists on the stems, and mild dwarfing of the plant; Level 4, severe dwarfing of the plant, and death of the upper leaves.
[0145] Disease index = ∑ (disease level × number of diseased plants at that level) / (highest disease level × total number of plants surveyed) × 100
[0146] Control effect (%) = [(disease index of blank control area - disease index of treated area) / disease index of blank control area] × 100
[0147] The results of field efficacy test of compounds Y03-Y05 against potato virus Y on tomatoes are shown in Table 5.
[0148] Table 5 Field efficacy determination of cytosine nucleoside compounds
[0149] Chemical treatment Preventive activity (%) Therapeutic activity (%) Y03 78.32 65.56 Y04 63.85 42.17 Y05 80.82 70.25 Ningnanmycin 69.91 58.84 Ethyl Copper Morphoguanidine 80.78 67.80
[0150] Note: The dosage of the 5 treatment groups is the same.
[0151] The results in Table 5 show that compound Y05 has good preventive and therapeutic activities against PVY virus disease on tomatoes in the field. The preventive activity of compound Y05 is 80.82%, which is significantly higher than that of the control agents ningnanmycin and ethyl copper morpholine; the therapeutic activity of compound Y05 is 70.25%, which is higher than that of the control agents ningnanmycin and ethyl copper morpholine.
[0152] Test Example 5
[0153] Identification of antiviral targets of the cytosine nucleoside compound Y05 of the present invention:
[0154] The 3D structure of compound Y05 was constructed using ChemOffice 19.0.0.22 software as the ligand molecule and optimized using the classic MM2 force field. The structure of the receptor protein was obtained from the Uniprot database (https: / / www.uniprot.org / ), and then non-essential water molecules were removed and polar hydrogen was added. The molecular docking software AutoDockVina 1.2.3 was used to perform molecular docking on the ligand molecule and the receptor molecule. The prediction results were analyzed using protein binding site prediction online servers such as Deepsite, PocketDepth and Fpocket to find the key binding sites, and finally the PyMOL 2.2.0 software was used for mapping.
[0155] The predicted binding site was mutated using a point mutation reagent, and the full-length gene fragment of TMV RdRp after point mutation was inserted into the Xba I and Xho I cloning sites of pET28a, and a C-terminal His fusion construct was generated after ligation with a homologous recombinase. The recombinant plasmid was transformed into Escherichia coli competent cells DH5α and identified by PCR and Sanger sequencing; the positive recombinant plasmid was induced to express the Y05 target protein attached with a histidine tag by Escherichia coli BL21 strain and purified. The protein mutant was pulled down by a biotinylated probe to analyze the binding site of compound Y05 with the key host target protein.
[0156] The antiviral target identification results of cytosine nucleoside compound Y05 are shown in Figures 1 to 3 .
[0157] Figure 1 The results showed that compound Y05 can bind well to the active cavity of RdRp protein and bind to the target protein through hydrogen bonding. Among them, the binding sites of Y05 and RdRp are ASP-114, GLU-149 and GLU-141.
[0158] Figures 2-3 The results showed that compound Y05 had strong binding ability with RdRp, with a dissociation constant of 44.24 μM ( Figure 2 ), after mutating the amino acids 114, 149 and 141 of the RdRp protein, the binding ability of compound Y05 to the mutant RdRp was weakened ( Figure 3 ), and identified the key amino acid sites of action.
[0159] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A glycine-based cytosine nucleoside compound, characterized in that: It has the structure shown in formula 1: In formula 1, n=0~6.
2. The method for preparing the glycine-based cytosine nucleoside compound according to claim 1, characterized in that: The following steps are involved: Mixing a glycine compound, cytosine nucleoside, a condensing agent and a first organic solvent to carry out a condensation reaction to obtain a condensation product; The condensation product, trifluoroacetic acid and a second organic solvent are mixed, and after deprotection, extraction, washing, separation, concentration and purification are sequentially performed to obtain a glycine-based cytosine nucleoside compound having a structure shown in Formula 1; The glycine compound has a structure shown in Formula 2: The cytosine nucleoside has a structure shown in Formula 3: The condensation product has a structure shown in Formula 4:
3. The preparation method according to claim 2, characterized in that: The mass ratio of the glycine compound to cytosine nucleoside is 5-15:4-6.
4. The preparation method according to claim 2, characterized in that: The condensing agent includes O-benzotriazole-tetramethyluronium hexafluorophosphate or 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; the mass ratio of the condensing agent to cytosine nucleoside is 1:1-2; The first organic solvent includes N,N-diisopropylethylamine or triethanolamine; the usage ratio of the condensing agent to the first organic solvent is 2-6 g:5-10 mL.
5. The preparation method according to claim 2 or 4, characterized in that: The condensation reaction temperature is 4 to 25° C. and the reaction time is 2 to 12 hours.
6. The preparation method according to claim 2, characterized in that: The usage ratio of the condensation product to trifluoroacetic acid is 2-6 g:1-4 mL.
7. The preparation method according to claim 2 or 6, characterized in that: The temperature of the deprotection is 18-25° C., and the time is 1-3 hours.
8. The preparation method according to claim 2, characterized in that: The purification is carried out using a C18 chromatographic column, and the reagents used for the purification include acetonitrile and water, and the volume ratio of the acetonitrile to water is 1-3:4-7.
9. Use of the glycine-based cytosine nucleoside compound according to claim 1 or the glycine-based cytosine nucleoside compound prepared by the preparation method according to any one of claims 2 to 8 in the preparation of insecticides, fungicides or anti-plant virus agents.
10. A bactericidal and antiviral composition for plant diseases, characterized in that: Calculated by mass percentage, the composition comprises 1-99% of the glycine-based cytosine nucleoside compound according to claim 1 and 1-99% of a drug; the drug is a bactericide or an antiviral agent.
